IKT · CIK 0001750149 · operating
Inhibikase Therapeutics, Inc. (IKT) is a biological products, (no diagnostic substances) company incorporated in DE, listed on the Nasdaq. With a market capitalization of $249 million, Inhibikase Therapeutics, Inc. is a micro-cap company. The stock currently trades at $1.96, down 4.63% today, with a 52-week range of $1.33–$2.58. The company trades at a trailing P/E of 4.4x.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.16 | $-1.16 | +67.5% | |
| 2023 | $-3.57 | $-3.57 | -395.8% | |
| 2022 | $-0.72 | $-0.72 | — | |
| 2021 | — | — | — |